Veros COVID-19 is a handheld device that delivers lab-quality molecular results – 97.9% accuracy – in about 15 minutes, right at the point of care.

Image source: Sense Biodetection 

Sponsored • Handheld diagnostics

Veros™ COVID-19 test now available in Europe

Handheld, instrument-free test delivers lab-quality molecular results – 97.9% accuracy – in about 15 minutes, right at the point of care.

More than 500 million people worldwide have been infected with COVID-19. More cases occur daily.1 The need for fast, reliably accurate, and accessible test results remains a critical unmet need. 

Meet Veros COVID-19. The first and only fully integrated, instrument-free molecular diagnostic test that provides laboratory-quality molecular results in about 15 minutes right at the point of care. Patients don’t have to wait for answers. Healthcare providers can make confident, timely decisions for better care.

Proven effective

One of the most comprehensive COVID-19 diagnostic testing clinical trials conducted to date proved the performance of Veros COVID-192:

  • 97.9% accuracy
  • 95.2% sensitivity 
  • 99.5% specificity

Where the performance of some antigen tests has waned with new variants3-7, Veros COVID-19 has maintained 100% conservation in all Variants of Interest and Concern identified to date by WHO and the US CDC, including Delta and Omicron.

The need for reliably fast, accurate, and accessible COVID-19 test results...
The need for reliably fast, accurate, and accessible COVID-19 test results remains critical. To help meet this need, Veros COVID-19 is now available in Europe.

Image source: Sense Biodetection 

Proven easy to use, easy to deploy

100% of all participants in the clinical trial agreed that Veros COVID-19 was easy to use and that it delivered simple-to-read, understandable results.2 

Veros COVID-19 requires no formal laboratory training. No instrument. No external power supply. And minimal hands-on time from start to finish. 

Just swab, swirl, and test. See clear results in about 15 minutes. Then dispose of the device when done. Easy.

Veros COVID-19 delivers fast, accurate, and instrument-free testing wherever...
Veros COVID-19 delivers fast, accurate, and instrument-free testing wherever you need it.

Image source: Sense Biodetection 

The answer is within reach

Advantages over rapid antigen testing 

  • Over 1000x more sensitive than antigen tests8 
  • On average, molecular tests detect ~30% more true positives8 
  • Studies suggest some antigen tests may fail to detect variants such as Omicron3-7 
  • PCR tests detect virus sooner than rapid antigen tests9 

Fast results 

  • Diagnose and treat within an office visit
  • No waiting for lab results 

Improved throughput 

  • Clinic can run one or dozens of tests at the same time for more efficient patient throughput and productive large-scale testing
  • No service downtime or machine setup – ever 

Greater economy 

  • No capital expense 
  • No need to calibrate, validate, or maintain instruments 

About Sense Biodetection

Sense Biodetection is a global molecular diagnostics company focused on empowering patients and transforming healthcare access and affordability by delivering lab-quality results through easy-to-use, rapid, disposable molecular tests without the constraints of an instrument. Our Veros platform is designed to enable widespread testing through enhanced patient access, improve patients’ health, and lower systemic healthcare costs. 

To learn more, visit https://sense-bio.com/

Veros COVID-19 is intended for the detection of SARS-CoV-2 RNA in nasal samples from symptomatic patients suspected of COVID-19 infection by qualified healthcare professionals, in near-patient settings.

Available in select EU markets, pending UK DHSC review and approval.


  1. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Accessed May 5, 2022, at https://covid19.who.int/
  2. Prospective, multicentre study of 292 evaluable subjects conducted during Delta and Omicron variant surges. Veros COVID-19 results were compared directly against a highly sensitive, state-of-the-art, CE-marked qRT-PCR test. Data on file. 
  3. Olearo F, et al. Journal of Clinical Virology. 2021;137:104782. 
  4. Brueck H, Gal S. Business Insider. December 23, 2021. 
  5. Slabodkin G. Medtech Dive. December 29, 2021. 
  6. Anthes E. New York Times. August 11, 2021. 
  7. Anthes E,  Jewett C. New York Times. January 5, 2022. 
  8. Analytic performance data on file. Sense Biodetection. 
  9. Guglielmi G. Nature. 2021;590:202-205.


Source: Sense Biodetection

10.06.2022

Read all latest stories

Related articles

Photo

News • Spit take

Portable diagnostic detects SARS-CoV-2 RNA and antibodies

The prototype device combines eRapid and SHERLOCK technologies into a single, postcard-sized system that can simultaneously detect the presence of both SARS-CoV-2 RNA and antibodies in a patient’s…

Photo

News • Deep mutational scanning for SARS-CoV-2

Preparing rapid tests for future coronavirus variants

How can rapid antigen tests be adjusted to reliably detect future variants of SARS-CoV-2? A research team funded by the National Institutes of Health is currently working on finding an answer.

Photo

Sponsored • Precise, affordable, and portable

A health testing platform that consolidates multimodal and multiplex testing to one device

Fluxergy envisions that a fully articulated democratized testing health system has the potential to reduce the likelihood and the ultimate severity of pandemics like Covid-19. Our mission is to…

Related products

Subscribe to Newsletter